Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.
Content
Cáncer de mama
15m 18s
How I treat metastatic triple-negative breast cancer (TNBC)
Publicado11 Jul 2022
Triple Negative MBC patients have poorer overall survival compared to other subtypes & they also receive lowest number lines of treatment. ~20% of Triple Negative MBC patients do not even receive 2nd line of treatment, making the choice 1st line therapy critical. Immunotherapy & PARP inhibitors have shown promising efficacy in 1st Line Triple Negative MBC for patients who are positive for these biomarkers. Newer treatment options like PI3K/AKT/mTOR inhibitors, Epithelial Antigen (TROP-2) targeted drugs are being studied in Triple Negative MBC. Anti Trop-2 Antibody Sacituzumab govitecan has shown promising efficacy in treatment of Metastatic TNBC in later lines. Androgen receptor targeted drugs are under investigation for small subset of patients with androgen receptor positivity.
